A comprehensive review on non-clinical methods to study transfer of medication into breast milk - A contribution from the ConcePTION project.
Breastfeeding plays a major role in the health and wellbeing of mother and infant. However, information on the safety of maternal medication during breastfeeding is lacking for most medications. This leads to discontinuation of either breastfeeding or maternal therapy, although many medications are likely to be safe. Since human lactation studies are costly and challenging, validated non-clinical methods would offer an attractive alternative. This review gives an extensive overview of the non-clinical methods (in vitro, in vivo and in silico) to study the transfer of maternal medication into the human breast milk, and subsequent neonatal systemic exposure. Several in vitro models are available, but model characterization, including quantitative medication transport data across the in vitro blood-milk barrier, remains rather limited. Furthermore, animal in vivo models have been used successfully in the past. However, these models don't always mimic human physiology due to species-specific differences. Several efforts have been made to predict medication transfer into the milk based on physicochemical characteristics. However, the role of transporter proteins and several physiological factors (e.g., variable milk lipid content) are not accounted for by these methods. Physiologically-based pharmacokinetic (PBPK) modelling offers a mechanism-oriented strategy with bio-relevance. Recently, lactation PBPK models have been reported for some medications, showing at least the feasibility and value of PBPK modelling to predict transfer of medication into the human milk. However, reliable data as input for PBPK models is often missing. The iterative development of in vitro, animal in vivo and PBPK modelling methods seems to be a promising approach. Human in vitro models will deliver essential data on the transepithelial transport of medication, whereas the combination of animal in vitro and in vivo methods will deliver information to establish accurate in vitro/in vivo extrapolation (IVIVE) algorithms and mechanistic insights. Such a non-clinical platform will be developed and thoroughly evaluated by the Innovative Medicines Initiative ConcePTION.
['Nauwelaerts|Nina|N|', 'Deferm|Neel|N|', 'Smits|Anne|A|', 'Bernardini|Chiara|C|', 'Lammens|Bart|B|', 'Gandia|Peggy|P|', 'Panchaud|Alice|A|', 'Nordeng|Hedvig|H|', 'Bacci|Maria Laura|ML|', 'Forni|Monica|M|', 'Ventrella|Domenico|D|', 'Van Calsteren|Kristel|K|', 'DeLise|Anthony|A|', 'Huys|Isabelle|I|', 'Bouisset-Leonard|Michele|M|', 'Allegaert|Karel|K|', 'Annaert|Pieter|P|']
D000818:Animals D005260:Female D006801:Humans D007223:Infant D007231:Infant, Newborn D007774:Lactation D008321:Mammary Glands, Animal D042361:Mammary Glands, Human D018811:Maternal Exposure D008895:Milk, Human D023421:Models, Animal D008954:Models, Biological D004364:Pharmaceutical Preparations D010599:Pharmacokinetics D018570:Risk Assessment D013045:Species Specificity
Breastfeeding Infants Maternal medication Lactation In vitro In vivo Neonates Pharmacokinetics PBPK Medication exposure